Loading…
20/20 Biolabs, Inc. is projected to decline to $0.9365 by 2027, a -3% move from its current price of $0.97. AIDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.9095 | $0.9704 | $1.04 | +0.04% |
| May 30 | $0.8857 | $0.9707 | $1.06 | +0.08% |
| May 31 | $0.868 | $0.9711 | $1.09 | +0.12% |
| Jun 1 | $0.8533 | $0.9715 | $1.11 | +0.15% |
| Jun 2 | $0.8407 | $0.9719 | $1.12 | +0.19% |
| Jun 3 | $0.8295 | $0.9722 | $1.14 | +0.23% |
| Jun 4 | $0.8193 | $0.9726 | $1.15 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8193 | $0.9726 | $1.15 | +0.27% |
| Week 2 | $0.7652 | $0.9752 | $1.24 | +0.54% |
| Week 3 | $0.7265 | $0.9779 | $1.32 | +0.81% |
| Week 4 | $0.6958 | $0.9805 | $1.38 | +1.08% |
| Week 5 | $0.67 | $0.9832 | $1.44 | +1.36% |
| Week 6 | $0.6476 | $0.9858 | $1.50 | +1.63% |
| Week 7 | $0.6279 | $0.9885 | $1.56 | +1.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
20/20 Biolabs, Inc. is a healthcare company that develops AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It offers OneTest for Cancer, a multi-cancer early detection (MCED) test, and OneTest for Longevity, which measures inflammatory biomarkers.
It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups.
The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. It was incorporated in 2000 and is based in Gaithersburg, Maryland.
20/20 Biolabs, Inc. trades as AIDX in the Healthcare sector. It is currently priced at $0.98 per share and has a market capitalization of $10.27M, ranking 5146. The current price outlook shows a stable near-term level with a mixed longer-term path according to the year-by-year forecast.
In 2026, the forecast is flat around the current level (min $0.98, avg $0.98, max $1.46) with ROI of 0 and NEUTRAL sentiment. The long-run picture turns more constructive after 2030, with positive ROIs emerging in 2031 and beyond, and targets rising toward the 2030s and 2040s. By 2050, the forecast envisions a higher average price and a substantially larger potential upside (avg $2.08, max $4.78) with a strong bullish signal.
A major floor 56.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 84.5% above — a clean break opens room to run.
A major ceiling 2358.8% above — clearing it would confirm fresh momentum.
Key AIDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AIDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.09 | Sell | $1.08 | Sell |
| MA 10 | $1.23 | Sell | $1.18 | Sell |
| MA 20 | $1.35 | Sell | $1.35 | Sell |
| MA 50 | $1.62 | Sell | $3.19 | Sell |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 14.59 | Buy |
| Stoch RSI (14) | 49.74 | Neutral |
| CCI (20) | -193.12 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -29.20 | Sell |
| Bollinger %B (20,2) | -0.03 | Buy |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.14 | Sell |
| Awesome (5,34) | -0.41 | Sell |
| Ultimate (7,14,28) | 16.50 | Buy |
| Momentum (10) | -0.49 | Sell |
| Aroon Osc (25) | -96.00 | Sell |
| Hull MA (9) | 0.94 | Buy |
| ADX (14) | 73.69 | Sell |
| ATR (14) | 0.09 | Info |
The 30-day technical picture is NEUTRAL with RSI 14 at 10, suggesting an oversold condition near support. The price sits at the $0.98 support level, within a 30-day range of $0.6301 to $1.52, and faces resistance at $1.85.
The SMA50 is $1.68, and the price remains below this level, indicating current softness relative to the short-term trend. These readings imply limited near-term upside potential unless price breaks above $1.85, your defined resistance, while holding the $0.98 support.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.97 | $0.97 | $1.43 | 0% | Neutral | |
| $0.6035 | $0.9365 | $1.57 | -3% | Neutral | |
| $0.5346 | $0.9183 | $1.67 | -5% | Neutral | |
| $0.3901 | $0.7342 | $1.42 | -24% | Bearish | |
| $0.3876 | $0.7956 | $1.62 | -18% | Bearish | |
| $0.4739 | $1.05 | $2.24 | +9% | Neutral | |
| $0.5305 | $1.18 | $2.60 | +22% | Bullish | |
| $0.5832 | $1.30 | $2.96 | +34% | Bullish | |
| $0.5068 | $1.13 | $2.59 | +16% | Neutral | |
| $0.4598 | $1.02 | $2.35 | +5% | Neutral | |
| $0.7319 | $1.63 | $3.74 | +68% | Bullish | |
| $0.9073 | $2.02 | $4.64 | +108% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.97 | $0.97 | $1.17 | +0.00% |
| June 2026 | $0.8442 | $1.03 | $1.33 | +6.69% |
| July 2026 | $0.7986 | $1.00 | $1.34 | -2.92% |
| August 2026 | $0.7528 | $0.9669 | $1.32 | -3.76% |
| September 2026 | $0.7678 | $1.00 | $1.40 | +3.77% |
| October 2026 | $0.76 | $1.01 | $1.44 | +0.58% |
| November 2026 | $0.7081 | $0.9539 | $1.38 | -5.48% |
| December 2026 | $0.7073 | $0.9661 | $1.43 | +1.28% |
Click any year to see its month-by-month AIDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect AIDX to range from $0.97 to $1.43 through 2026. The $0.97 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The AIDX price prediction for 2027 points to an average of $0.9365 (low $0.6035, high $1.57) — a potential decline of -3% on today's $0.97. Price action looks broadly range-bound.
In 2028, AIDX is projected to trade between $0.5346 and $1.67, averaging $0.9183 — a potential decline of -5% from today's $0.97. That is -2% versus the projected 2027 average. A consolidation phase looks the most probable path here.
20/20 Biolabs, Inc.'s 2029 outlook centres on $0.7342, within a $0.3901 to $1.42 range. That is -20% versus the projected 2028 average. That marks a -24% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, AIDX could reach as high as $1.62, with a base case around $0.7956 and support toward $0.3876 — roughly -18% from $0.97. Expect choppier, lower action through this leg of the cycle.
Expect AIDX to range from $0.4739 to $2.24 through 2031. The $1.05 average target implies a +9% move from current prices. That is up +32% on the projected 2030 average. Price action looks broadly range-bound.
The AIDX price prediction for 2032 points to an average of $1.18 (low $0.5305, high $2.60) — a potential gain of +22% on today's $0.97. Buyers look set to stay in control over this stretch.
In 2033, AIDX is projected to trade between $0.5832 and $2.96, averaging $1.30 — a potential gain of +34% from today's $0.97. That is up +10% on the projected 2032 average. Momentum favours further upside here.
20/20 Biolabs, Inc.'s 2034 outlook centres on $1.13, within a $0.5068 to $2.59 range. That is -13% versus the projected 2033 average. That marks a +16% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, AIDX could reach as high as $2.35, with a base case around $1.02 and support toward $0.4598 — roughly +5% from $0.97. Price action looks broadly range-bound.
Expect AIDX to range from $0.7319 to $3.74 through 2040. The $1.63 average target implies a +68% move from current prices. That is up +59% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The AIDX price prediction for 2050 points to an average of $2.02 (low $0.9073, high $4.64) — a potential gain of +108% on today's $0.97. Momentum favours further upside here.
Investing $1,000 in AIDX today (≈ 1,030.927835 AIDX) could be worth
$2,078.49
+$1,078.49 (+108%) by 2050 · US Dollar
Based on the average projected AIDX price of $2.02 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AIDXwould be worth at today's price.
$1,000 invested in AIDX on Feb 19, 2026 (≈ 41.928721 AIDX) would be worth
$40.67
-$959.33 (-95.9%) today · 0.04× · US Dollar
Based on a AIDX entry price of $23.85 vs. today's $0.97.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.29 | $751.94 | -24.8% |
| 1 month ago | $1.53 | $633.99 | -36.6% |
| 3 months ago | $4.08 | $237.75 | -76.2% |
| All time ago | $23.85 | $40.67 | -95.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AIDX forecast.
Our base-case forecast reaches $1.90 around 2050.
Implied market cap at $1.90: $20.16M
The multi-year forecast shows a meaningful shift from near-term weakness to longer-term growth. In 2029 the average price is $0.7501 with a bearish sentiment and a -23.5% ROI, followed by 2030 with an average of $0.8027 and a -18.1% ROI. From 2031 onward, the picture improves: 2031 average $1.06 (ROI 8.5%), 2032 $1.20 (22.8%), 2033 $1.30 (32.7%).
The forecast continues to rise into the 2040s, with 2040 average $1.63 and ROI 66.4% (bullish), and culminates in 2050 with an average of $2.08 and ROI 111.9% (bullish). These figures reflect a long-run trajectory toward higher prices, albeit with substantial near-term volatility and risk during the 2029–2030 window.
Tap a question to reveal the answer.
2030 average price is $0.8027 with a minimum of $0.3906 and a maximum of $1.63. The ROI is -18.1% and the sentiment is BEARISH.
The forecast shows mixed near-term performance, with negative ROIs in 2027–2030 (e.g., 2029 ROI -23.5%, 2030 ROI -18.1%). The outlook improves after 2031, with positive ROIs and rising averages through 2032–2050 (e.g., 2050 ROI 111.9%, avg $2.08). These are estimates and involve uncertainty.
Yes. The forecast includes max values above $2 in multiple years: 2031 max $2.26, 2032 max $2.66, 2033 max $2.97, and later years such as 2040 max $3.75 and 2050 max $4.78.
RSI14 is 10, indicating oversold conditions. The price is near support at $0.98 with a 30-day range of $0.6301 to $1.52 and resistance at $1.85. The SMA50 is $1.68, and the price remains below this level.
2050 forecast shows min $0.9346, avg $2.08, max $4.78 with ROI 111.9% and sentiment BULLISH.
20/20 Biolabs, Inc. Community Discussion
0Share your 20/20 Biolabs, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.